- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05492045
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
April 23, 2023 updated by: InventisBio Co., Ltd
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
144
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bingxin Xue
- Phone Number: (86)21-50663661
- Email: bingxin.xue@inventisbio.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Not yet recruiting
- Shanghai Chest Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310005
- Recruiting
- Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject with histologically proven, locally advanced or metastatic NSCLC for which has no standard treatment or the subject has been previously treated with first- or second-line systemic therapy.
- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA. Historical, local laboratory result (up to 5 years prior to this study) can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C mutation by a local laboratory.
- Subject has measurable disease according to RECIST v1.1. For phase 1b subjects who have no measurable lesions but whose disease can be evaluated are also acceptable.
Exclusion Criteria:
- Subject with unstable or progressive central nervous system (CNS) metastases.
- Subjects with clinically significant cardiovascular disease.
- Subject with interstitial lung disease (ILD) or any active systemic infection including but not limited to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Subject has impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption or metabolism of oral medications.
- Subject is pregnant or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b Dose escalation of D-1553 combination therapies
Phase 1b will determine maximal tolerated dose and/or recommended phase 2 dose of D-1553 in combination with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
|
D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Standard treatment of NSCLC.
|
Experimental: Phase 2 of D-1553 combination therapies
Phase 2 will evaluate the efficacy and safety of D-1553 combined with immunotherapy or targeted therapy in patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
|
D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Standard treatment of NSCLC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject incidence of Dose-limiting toxicities (DLT)
Time Frame: Through out the DLT period, approximately 21 days
|
Subject incidence of Dose-limiting toxicities (DLT)
|
Through out the DLT period, approximately 21 days
|
Number of subjects participants with adverse events
Time Frame: Till study completion, approximately 3 years
|
Number of subjects participants with adverse events
|
Till study completion, approximately 3 years
|
Antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation
Time Frame: Till study completion, approximately 3 years
|
Overall Response Rate (ORR, Complete Response [CR] + Partial Response [PR])
|
Till study completion, approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 13, 2022
Primary Completion (Anticipated)
April 1, 2024
Study Completion (Anticipated)
December 1, 2024
Study Registration Dates
First Submitted
August 5, 2022
First Submitted That Met QC Criteria
August 5, 2022
First Posted (Actual)
August 8, 2022
Study Record Updates
Last Update Posted (Actual)
April 25, 2023
Last Update Submitted That Met QC Criteria
April 23, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1553-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on D-1553
-
InventisBio Co., LtdActive, not recruiting
-
InventisBio Co., LtdInxMed (Shanghai) Co., Ltd.Recruiting
-
InventisBio Co., LtdCompleted
-
InventisBio Co., LtdMerck Sharp & Dohme LLCActive, not recruitingNSCLC | Solid Tumor, Adult | CRCUnited States, Taiwan, Australia, Korea, Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
University of MessinaCompletedChronic Periodontitis
-
InventisBio Co., LtdActive, not recruiting
-
Lee's Pharmaceutical LimitedUnknownOvarian Epithelial Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerChina
-
Rhode Island HospitalVirtually Better, Inc.CompletedMental Health | Human Immunodeficiency VirusUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance